Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and IMRT in Cisplatin-Ineligible Advanced Head and Neck Squamous Cell Carcinoma
NCT04533750Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of peposertib in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting toxicities at 11 weeks and Maximum tolerable dose at 11 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04533750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533750.